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Abstract 
Background: Previous studies suggest that higher plasma concentrations of several lipid 
molecules are associated with higher lipid core burden index (LCBI) NIRS imaging. The aim 
of this study was to investigate whether an association between plasma lipids depends on 
plaque morphology (thin cap fibrous atheroma [TCFA] vs. non-TFCA) as measured by near-
infrared spectroscopy–intravascular ultrasound (NIRS-IVUS). 
Methods: 64 patients retrospectively enrolled were diagnosed with stable coronary artery 
disease or acute coronary syndrome who underwent NIRS-IVUS imaging. Before 
percutaneous coronary intervention, blood samples were collected for measurement of serum 
levels of total cholesterol (TC), low-density lipoprotein cholesterol (HDL-C), high-density 
lipoprotein cholesterol (HDL-C) and triglycerides. Patients were divided into two groups 
based on maxLCBI4mm and IVUS imaging. Those with maxLCBI4mm ≥ 323 were included into 
TCFA group (n = 35) while others were assigned to the non-TCFA group (n = 29).  
Results: Thin cap fibrous atheroma (TCFA) lesions were significantly longer than the non-
TCFA lesions (25.66 ± 9.56 vs. 17.03 ± 9.22, p = 0.001). TCFA characterizes greater plaque 
burden (78.4 [70.9, 82.2] vs. 72.70 [64.77, 76,05]; p = 0.021) and plaque volume (176.1 
[110.75, 247.5] vs. 68.1 [55.58, 143.35]; p = 0.000) as compared to non-TCFA. In TCFA 
suspected lesions, there was no correlation between maxLCBI4mm and LDL levels (r = 0.105, 
p = 0.549) nor TC levels (r = –0.035, p = 0.844) but a negative correlation was found between 
HDL-C and maxLCBI4mm (r = –0.453, p = 0.007).  
Conclusions: The present study showed that there was no correlation between plasma LDL-
C, TCH and TG level and the amount of lipids in coronary plaque assessed by NIRS in both 
TCFA and non-TCFA groups. Only HDL-C correlated with maxLCBI4mm in TCFA lesions. 
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Introduction 
Stable coronary artery disease (SCAD) is a common cause of death. According to the 
European Heart Network Report from 2017 Ischemic Heart Disease (IHD) is responsible for 
862,000 deaths a year (19% of all deaths) among men and 877,000 deaths (20%) among 
women in Europe each year [1]. Untreated SCAD may be followed by acute coronary 
syndrome (ACS). In most cases (approximately 75%) ACS is caused by a rupture or erosion 
of the vulnerable atherosclerotic plaque which leads to an occlusion of the vessel [2–4]. 
Vulnerable plaques are considered to be thin cap fibrous atheroma (TCFA) [5, 6]. TCFAs 
were defined by Burke et al. [7] as a necrotic and lipid-rich core plaque covered with fibrous 
cap < 65 µm measured by optical coherence tomography (OCT). The lipid-rich core 
containing plaques can also be detected by near-infrared spectroscopy (NIRS) [8, 9], a 
catheter-based intravascular imaging device based on diffuse reflectance spectroscopy. Its 
adjustment to intravascular ultrasound (IVUS) enables the periprocedural analysis of the 
chemical composition of plaque and distinguishes lipid-rich lesions. The amount of lipids is 
measured as a lipid core burden index (maxLCBI4mm). Roleder et al. [10] and Inaba et al. [11] 
identified TCFA as lesions with maxLCBI4mm ≥ 323. 
High cholesterol levels are strongly associated with SCAD [12–14]. It is known that 
there is a positive relation between low-density lipoprotein cholesterol (LDL-C) and SCAD 
[15, 16]. In contrast, there is an inverse relationship between high-density lipoprotein 
cholesterol (HDL-C) and the risk of SCAD [17, 18]. It was established that both LDL-C [19] 
and HDL-C [20] are associated with plaque volume. However, the influence of lipid plasma 
levels on the chemical composition of the plaque measured by NIRS remains unknown. 
The aim of this study was to investigate whether an association between plasma lipids 
depends on plaque morphology (TCFA vs. non-TFCA) as measured by NIRS-IVUS. 
 
Materials and methods 
Study population 
All patients diagnosed with SCAD or ACS between 2012 and 2015 who underwent NIRS-
IVUS imaging were screened for inclusion in this study. The SCAD and ACS management 
met the criteria of the European Society of Cardiology [21]. Patients with stent restenosis as a 
target lesion, renal failure (creatinine > 1.5 mg/dL), hemodynamic compromise and contrast 
allergy were excluded from the study. The percutaneous coronary intervention (PCI) was 
performed under angiography guidance, and NIRS-IVUS data were not used for this purpose. 
Analyzed segments were targeted in the imaged artery by NIRS-IVUS. None of the patients 
developed any complications related to NIRS-IVUS imaging.  
Before or after the PCI blood samples were collected from every patient on day 1, after 
fasting conditions for the measurement of serum levels of TC, LDL-C, HDL-C and 
triglyceride (TG). All of them were measured enzymatically using standard methods. Clinical 
demographics and medical history were obtained from hospital records. The study group 
consisted of 64 lesions analyzed in 64 patients. Patients were divided into two groups based 
on maxLCBI4mm results. Those with maxLCBI4mm ≥ 323 were included in the TCFA group (n 
= 35) while others were assigned to the non-TCFA group (n = 29). The study conformed to 
the Declaration of Helsinki. Due to retrospective design of the study, further application was 
not needed. 
 
NIRS-IVUS analysis 
The NIRS-IVUS analysis was performed in culprit lesions using standard protocol 
before stent implantation. All NIRS-IVUS examinations were performed after heparin 
anticoagulation (activated clotting time > 250 s) and following intracoronary nitroglycerine 
(100–200 μm) administration. The 2.4 Fr. TVC Insight Catheter (InfraReDx, TVC Imaging 
System™, Burlington, MA USA) was positioned at least 10 mm distal to the imaging target 
lesion. Subsequently, the automated pullback was started with at 0.5 mm/s (240 rotations/min) 
until the TVC catheter entered the guiding catheter. Measurements were made every 1 mm in 
region of interest (ROI), and the target lesion was required to be at least 4 mm long. 
Quantitative grey-scale IVUS measurements were performed every 1 mm in the scanned 
coronary segment before stent implantation. Cross-sectional images were quantified for lumen 
diameters and area, external elastic lamina (EEM) diameters and area, total plaque area, 
plaque burden, and lumen and EEM eccentricity by one observer. Plaque burden was 
calculated as total plaque area divided by EEM CSA × 100 (%). The remodeling index (RI) 
was calculated by dividing EEM area at the minimal lumen area (MLA) by the reference 
EEM area. Lesions with RI ≤ 0.95 were defined as negatively remodeled, while those with RI 
≥ 1.05 were defined as positively remodeled. RI between these values was taken as a non-
remodeled vessel. 
The chemical composition of the plaque in ROI was acquired using NIRS. The lipid-
rich plaques are displayed on chemogram on which the X-axis shows the pullback position (1 
pixel every 0.1 mm) and Y-axis displays the circumferential position (1 pixel every 1⁰ ). 
Based on chemogram the Lipid Core Burden Index in 4 mm was measured. There was a 
fraction of pixels indicating lipids (yellow pixels) within the ROI. The LCBI with 
maxLCBI4mm was measured automatically by NIRS software. TCFA suspected lesions were 
defined as maxLCBI4mm ≥ 323.  
NIRS-IVUS data were analyzed off-line using CAAS intravascular software (Pie 
Medical Imaging BV, Maastricht, The Netherlands). 
 
Statistical analysis 
Normality of variables was assessed by the Kolmogorov-Smirnov test. For normally 
distributed data values were presented as the mean with a standard deviation (± SD). Non-
normally distributed continuous variables were displayed as a median with interquartile 
intervals (IQR, 1st, 3d). Categorical data were shown as the number or percentage (%). For the 
normally distributed group comparison, the one-way ANOVA was used. Non-normally 
distributed data were compared using the Mann-Whitney test. The correlation was measured 
using the Pearson correlation coefficient for normally distributed values and the Spearman 
rank-order correlation for non-normally distributed variables. The categorical data were 
compared using the Fischer exact test or χ2 test. A value of p < 0.05 was considered 
statistically significant. SPSS version 25.0 (SPSS, Inc., Chicago, Illinois) was used for 
statistical analysis.  
 
Results 
Patients characteristics 
The baseline characteristics are summarized in Table.1. Between 2012 and 2015 64 
patients were enrolled in the study. All patients included underwent PCI followed by stent 
deployment. Patients from the TCFA group were not -significantly younger than patients from 
non-TCFA group (63.2 ± 11.37 vs. 66.64 ± 9.8; p = 0.176). All patients in both groups had 
dyslipidemia. There were no significant differences in the percentage of patients who had 
hypertension (85.7% vs. 93.1%, p = 0.209) or diabetes mellitus (42.8% vs. 31%, p = 0.331) in 
TCFA or non-TCFA groups. At the time of the procedure, the percentage of patients treated 
with statins was similar in both groups (85.7% vs. 86.2%; p = 0.719). 9 (25.7%) of TCFA 
patients and 10 (34.5%) of non-TCFA patients presented with a history of myocardial 
infarction (p = 0.445).  
 
IVUS lesion analysis 
Intravascular ultrasound results are reported in Table.3. The NIRS-IVUS analysis was 
performed during coronary angiography. TCFA lesions were significantly longer than non-
TCFA lesions (25.66 ± 9.56 vs. 17.03 ± 9.22; p = 0.001). TCFA is characterized by greater 
plaque burden (78.4 [70.9, 82.2] vs. 72.70 [64.77, 76,05]; p = 0.021) and plaque volume 
(176.1 [110.75, 247.5] vs. 68.1 [55.58, 143.35]; p = 0.000) as compared to non-TCFA. The 
values of lumen volume (114.800 [86.100, 137.90] vs. 75.10 [55.75, 128.60]; p = 0.05) and 
EEM volume (301.6 [212.9, 393.7] vs. 153.2 [105.85, 272.1]; p = 0.003) were also higher in 
TCFA group. According to minimal lumen area and minimal lumen diameter there were no 
significant differences comparing both groups (respectively, p = 0.69, p = 0.334).  No 
difference was found in RI for both groups as well (1.02 [0.8, 1.27] vs. 1.00 [0.84, 1.44]; p = 
0.69). 
 
Association between NIRS analysis and lipid plasma levels 
Comparing TCFA to non-TCFA group, the differences in the levels of LDL-C (80.00 
[69.00, 111.00], vs. 72.00 [58.50, 97.50]; p = 0.43), HDL-C (39.50 [35.75, 46.00] vs. 42.00 
[33.50, 53.00]; p = 0.47), TC (146.00 [122.00, 181.00] vs 140.00 [120.50, 167.50; p = 0.80) 
and TG (119.00 [74.00, 160.00] vs. 102.00 [83.50, 120.50]; p = 0.34) were not statistically 
significant. Also, the number of patients with LDL > 70 was not significantly higher in TCFA 
group as compared to non-TCFA group (24 vs. 15; p = 0.223). The summary of lipid plasma 
levels is listed in Table 2.  
In non-TCFA group there was no significant correlation between maxLCBI4mm and 
LDL levels (r = –0.55, p = 0.783), TC levels (r = –0.133, p = 0.498) nor HDL-C levels (r = –
0.062, p = 0.754). In TCFA lesions there was also no correlation between maxLCBI4mm and 
LDL levels (r = 0.105, p = 0.549) nor TC levels (r = –0.035, p = 0.844) but a negative 
correlation was found between HDL-C and maxLCBI4mm (r = –0.453, p = 0.007).  
 
Discussion 
The major findings of the present study are as follows: 1) there was no correlation 
between LDL-C, TC and TG plasma levels and the number of lipids in coronary plaque 
assessed by NIRS in both groups, 2) HDL-C correlated with maxLCBI4mm in TCFA lesions, 
3) there was no difference in LDL-C, HDL-C, TC and TG plasma levels in patients with 
TCFA compared to those with non-TCFA lesions, 4) based on IVUS analysis TCFA 
characterized greater values of plaque volume, plaque burden and stenosis length.  
A large number of patients suffering from SCAD has aroused an interest in the 
pathology of atherosclerotic plaque. The Dynamic Registry revealed that 6% of lesions being 
< 50% in severity during initial angiography progressed mainly as ACS [22]. It showed that 
there is a need for a new diagnostic approach to finding clinically silent plaques. Pathological 
studies have found TCFA lesions to be the main precursor of plaque rupture in patients 
suffering from ACS [6, 23]. It was distinguished by a fibrous cap thickness which was < 65 
µm, a small minimal lumen area, and a larger plaque burden [6]. This finding and the fact that 
an angiographic evaluation of the stenosis was not sufficient led to the development of 
intravascular imaging modalities which facilitated in vivo TCFA identification. Especially 
OCT imaging, due to its high resolution emerged as a favorable intravascular modality in 
confirming a vulnerable plaque presence. OCT measurements determined a borderline fibrous 
cap thickness of < 65 µm [6, 7, 24]. Also, studies evaluating multiple imaging modalities 
enabled TCFA identification using IVUS, NIRS-IVUS or VH-NIRS. IVUS, in contrast to 
OCT, IVUS enables deep penetration into the plaque. Roleder et al. [24] emphasized its 
superior role in the estimation of plaque burden, vessel remodeling, and plaque vulnerability 
identification. Based on its measurements TCFA was defined as a lesion with a plaque burden 
greater than 70%, and a minimal lumen area of 4 mm2 or less [25]. Those lesions were also 
associated with higher MACE rate [26] and  positive remodeling [27]. Based on the present 
results, TCFA is characterized by a greater plaque burden and plaque volume which 
corresponds to previous findings.  
The adjustment of NIRS to IVUS enables the periprocedural analysis of chemical 
composition of the plaque and distinguishes lipid-rich lesions. It was also believed that 
identification of lipid-rich plaques based on chemical analysis might point out lesions 
responsive to intensive lipid-lowering therapy. It not only plays a qualitative role but also 
enables the quantitative measurement of lipid content as a maxLCBI4mm [9, 28]. According to 
NIRS results, TCFA was described by Inaba et al. [11] as a lesion with a threshold of 
maxLCBI4mm ≥ 323. A statistically significant association between maxLCBI4mm and an 
increased incidence of MACE was also observed [29, 30].  
It is commonly known that higher LDL-C and TC plasma levels increase the risk of 
vulnerable plaque [18]. Some clinical trials showed that LDL-C lowering therapy decreases 
the risk of cardiovascular events. The influence of LDL-C reduction of lipid content measured 
by NIRS was found in the Yellow trial which showed a decrease in maxLCBI4mm after 
rosuvastatin intensive therapy [31]. Even though LDL-C is considered to be one of the main 
factors of SCAD, many patients presenting with SCAD have LDL-C within normal levels, 
which was shown in a study carried out by Sachdeva et al. [32] revealing that only 50.5% of 
the patients admitted with SCAD presented LDL-C levels greater than 100 mg/dL [32]. This 
may explain the lack of correlation between LDL-C and maxLCBI4mm for both groups in the 
present study. According to LDL-C plasma levels in TCFA and non-TCFA group, Nasu et al. 
[14] showed that in the TCFA group LDL-C levels were significantly higher than in the non-
TCFA group while a study conducted by Nagasawa et al. [33] revealed no difference between 
those groups and this is what was also demonstrated in the current study.  
High density lipoprotein cholesterol is inversely related to SCAD. Its main role is to 
remove the excessive cholesterol by transporting its particles from non-hepatic cells to the 
liver and other steroidogenic organs [34]. It is believed that it plays a pivotal role in the 
inhibition of atherosclerosis by reducing the migration of inflammatory cells into the artery 
wall and inhibiting LDL-C oxidation [35]. The Framingham Heart Study highlighted HDL-C 
as a risk factor for SCAD and considered it to be of greater importance as compared to LDL-
C [17]. A study conducted by Honda et al. [36] revealed that independent of statin use HDL-C 
inversely correlated with a change in lipid plaque composition assessed by NIRS. The 
mentioned study and other studies did not show an association between LDL and 
maxLCBI4mm, which indicates the role of HDL-C in plaque composition and also agrees with 
the findings of the present study [37, 38]. It suggests that HDL-C may decrease the 
vulnerability of the plaque, but this finding requires further investigation. 
As far as TG are concerned, it was shown that they were among factors inducing the 
plaque progression [39], but are not independently associated with CAD. Further studies 
focused on the relationship between lipid plasma levels and plaque morphology showed no 
relation between TG and maxLCBI4mm which was also found in the current study. 
It needs to be highlighted that only periprocedural lipid plasma levels were measured 
with no insight into long-term analysis. Danek et al. [40] studied the progression of 
atherosclerosis in SVG and revealed that in contrast to the LDL-C and TG measured annually, 
the periprocedural measurements showed no association with maxLCBI4mm. It was also found 
that annual measurements are more representative for the assessment of plaque morphology. 
It may explain the lack of correlation between lipid plasma levels and maxLCBI4mm in the 
present study.  
According to patients who had suffered from myocardial infarction in the past, there 
was no significant difference between the TCFA and non-TCFA group. What was found was 
that all these patients had a significantly lower maxLCBI4mm value which had probably 
occurred due to lipid-lowering therapy. 
 Limitations of the study 
This study involves a small number of patients which leads to an increased risk of 
selection bias. The main limitation of this study is the fact that the length of lipid-lowering 
therapy remains unknown and was not taken into account. Additionally, only the stented 
lesion was analyzed without insight into other plaques in the coronary tree which may have 
led to an inaccurate assessment of the association between lipid plasma levels and plaque 
morphology. A larger and prospective study is needed to verify the results of this study.  
 
Conclusions 
The major finding of the present study showed that there was no correlation between 
plasma LDL-C, TC and TG level and the number of lipids in coronary plaque assessed by 
NIRS in both TCFA and non-TCFA group. Only HDL-C correlated with maxLCBI4mm in 
TCFA lesions. There was also no difference in LDL-C, HDL-C, TC and TG in patients with 
TCFA compared to those with non-TCFA lesions. Based on IVUS analysis TCFA 
characterized greater values of plaque volume, plaque burden and stenosis length.  
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Table 1. Patient characteristics.  
 
TCFA (n = 35) 
Non-TCFA 
(n = 29) 
P 
Clinical 
demographics
  
  
Age [years] 63.2 ± 11.37 66.64 ± 9.8 0.176 
Women 9 (25.7%) 9 (31%) 0.637 
BMI [kg/m2] 27.2 ± 6.07 26.4 ± 4.95 0.625 
Prior MI  9 (25.7%) 10 (34.5%) 0.445 
Prior PCI  13 (37.1%) 13 (37.1%) 0.533 
Prior CABG  3 (8.5%) 2 (6.9%) 0.845 
Dyslipidemia  35 (100%) 29 (100%)  
Hypertension  30 (85.7%)  27 (93.1%) 0.209 
Diabetes mellitus  15 (42.8%) 9 (31%) 0.331 
Statin use  30 (85.7%) 25 (86.2%) 0.719 
Hemoglobin 12.97 ± 1.64 12.7 ± 2.5 0.635 
Creatinine 1.06 ± 0.26 1.01 ± 0.25 0.514 
GFR 68.62 ± 18.77 70.7 ± 16.04 0.767 
Procedural findings    
Indication for coronary angiography 
ACS  8 (22.85%) 8 (27.58%) 0.664 
Region of interest [mm] 25.66 ± 9.56 17.03 ± 9.22 0.001 
Imaged coronary artery  
Left main artery 1 (5.7%) 0 0.05 
Left descending artery 20 (57.1%) 11 (37.9%) 0.05 
Circumflex artery 9 (25.7%) 5 (17.2%) 0.05 
Right coronary artery 5 (14.3%) 13 (44.8%) 0.05 
Variables are displayed as mean ± standard deviation when a normal distribution is present, or as median (1st–3rd 
quartile) when there was not a normal distribution present. For each variable, the percentage of patients involved 
(n%) is given. ACS — acute coronary syndrome; BMI — body mass index; CABG — coronary artery bypass 
grafting; GFR — glomerular filtration rate; MI — myocardial infarction; PCI — percutaneous coronary 
intervention; TCFA — thin cap fibrous atheroma 
Table 2. Summary of lipid plasma levels. 
 TCFA (n = 35) Non-TCFA (n = 29) P 
Blood lipid levels    
LDL-C 80.00 (69.00, 111.00) 72.00 (58.50, 97.50) 0.43 
HDL-C 39.50 (35.75, 46.00) 42.00 (33.50, 53.00) 0.47 
TC 146.00 (122.00, 181.00) 140.00 (120.50, 167.50) 0.80 
TG 119.00 (74.00, 160.00) 102.00 (83.50, 120.50) 0.34 
Variables are displayed as mean ± standard deviation when a normal distribution is present, or as median (1st–3rd 
quartile) when there was not a normal distribution present. For each variable, the percentage of patients involved 
(n%) is given. HDL-C — high density lipoprotein cholesterol; LDL-C — low density lipoprotein cholesterol; TC 
— total cholesterol; TCFA — thin cap fibrous atheroma; TG — triglycerides 
 
Table 3. Summary of near-infrared spectroscopy–intravascular ultrasound (NIRS-IVUS) 
results. 
NIRS analysis    
maxLCBI4mm 551.0 (423.0, 697.0) 137 (27.0, 232.0) 0.000 
IVUS analysis    
Stenosis length 25.66 ± 9.56 17.03 ± 9.22 0.001 
Lumen volume 
114.800 (86.100, 
137.90) 
75.10 (55.75, 128.60) 0.05 
EEM volume 301.6 (212.9, 393.7) 153.2 (105.85, 272.1) 0.003 
EEM area at MLA 11.2 (9.5, 12.6) 10.0 (7.35, 11.6) 0.056 
Plaque volume 176.1 (110.75, 247.5) 68.1 (55.58, 143.35) 0.000 
Plaque burden 78.4 (70.9, 82.2) 72.70 (64.77, 76,05) 0.021 
Minimal lumen area 2.57 (1.9, 3.4) 2.60 (2.05, 3.22) 0.69 
Minimal lumen diameter 1.6 (1.5, 1.7) 1.60 (1.50, 1.80) 0.334 
MLD based on reference 1.7 (1.6, 2.0) 1.80 (1.65, 2.00) 0.047 
Remodeling index 1.02 (0.8, 1.27) 1.00 (0.84, 1.44) 0.69 
Variables are displayed as mean ± SD when a normal distribution is present, or as median (1st–3rd quartile) when 
there was not a normal distribution present. For each variable, the percentage of patients involved (n%) is given. 
EEM — external elastic lamina 
Figure 1. The plasma lipid levels in thin cap fibrous atheroma (TCFA) and non-TCFA group. 
Variables are displayed as median with 1st–3rd quartile. 
 
Figure 2. A–D. The correlations between low density lipoprotein cholesterol (LDL-C) (A), 
high density lipoprotein cholesterol (HDL-C) (B), total cholesterol (TC) (C), triglycerides 
(TG) (D) and maxLCBI4mm. A. Correlation between LDL-C in thin cap fibrous atheroma 
(TCFA) and non-TCFA group was respectively 0.105 (p = 0.549) and –0.55 (p = 0.783); B. 
Correlation between HDL-C in TCFA and non-TCFA group was respectively –0.453 (p = 
0.007) and –0.062 (p = 0.754); C. Correlation between TC in TCFA and non-TCFA group 
was respectively –0.035 (p = 0.844) and –0.133 (p = 0.498); D. Correlation between TG in 
TCFA and non-TCFA group was respectively 0.059 (p = 0.735) and –0.21 (p = 0.283). 
 



